Kardium Inc., the developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, secures $104million in new funding.
The lead investor in the round was Fidelity Management & Research Company, with additional participation from new investment Durable Capital Partners LP and funds and accounts handled by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc.
The business plans to utilise the money to expand its manufacturing team and capacity, finish the PULSAR clinical research in order to get regulatory permissions for the Globe System, and assemble a clinical support and commercial team in advance of the Globe System’s commercial launch.
Read also – IFS Acquired Copperleaf Technologies Inc
Kardium was established in 2007 under the direction of CEO Kevin Chaplin. The company has created the Globe Mapping and Ablation System, which consists of a sophisticated catheter with a 122-electrode array and cutting-edge software that allows for high-definition mapping, rapid pulmonary vein isolation, and atrial ablation anywhere on the catheter.
About Kardium Inc.
The fast-growing medical solutions business Kardium Inc. has created a cutting-edge technology to treat atrial fibrillation (AF), a condition that affects over 59 million individuals globally. With a single catheter that can perform atrial ablation, high-definition mapping, and single-shot pulmonary vein isolation, the Globe® Mapping and Ablation System is the most comprehensive treatment for AF. based in Vancouver, Canada, and established in 2007.
